Aromatase and breast cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Estrogen receptor-positive (ER+) breast cancer is a significant health concern.
• Aromatase inhibitors and antiestrogens are key treatments, but resistance can develop.
• Understanding resistance mechanisms is crucial for optimizing breast cancer therapy.

Purpose of the Study:

• To compare the antitumor efficacy of letrozole and tamoxifen in a preclinical model.
• To explore synergistic strategies for optimal use of these agents.
• To investigate mechanisms of resistance to letrozole and identify ways to overcome it.

Main Methods:

• Developed a preclinical model using MCF-7Ca human breast cancer cells in immunodeficient mice.
• Treated mice with letrozole, tamoxifen, or combination therapy.
• Analyzed signaling protein expression (ER, Her-2, MAPK pathway) in tumors.
• Tested combination therapies including EGFR/Her-2 inhibitors and Faslodex.

Main Results:

• Letrozole monotherapy demonstrated superior efficacy compared to other treatments.
• Switching to letrozole re-sensitized tumors previously resistant to tamoxifen.
• Tumors developed resistance to letrozole, associated with increased Her-2 and MAPK pathway activation.
• Inhibiting MAPK or EGFR/Her-2 pathways restored letrozole sensitivity.
• Combined letrozole and Faslodex treatment effectively inhibited tumor growth long-term.

Conclusions:

• Combined blockade of estrogen receptor and growth factor pathways may overcome resistance.
• Targeting both ER and growth factor-mediated transcription can delay resistance.
• This strategy holds promise for maintaining long-term growth inhibition in ER+ breast cancer.